|
1
|
Tiu R, Gondek L, O'Keefe C and Maciejewski
JP: Clonality of the stem cell compartment during evolution of
myelodysplastic syndromes and other bone marrow failure syndromes.
Leukemia. 21:1648–1657. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Steensma DP, Bejar R, Jaiswal S, Lindsley
RC, Sekeres MA, Hasserjian RP and Ebert BL: Clonal hematopoiesis of
indeterminate potential and its distinction from myelodysplastic
syndromes. Blood. 126:9–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qi H, Qingxia Z, Xiao L, Lingyun W, Feng
X, Zheng Z and Chunkang C: Recurrent abnormal clones in
myelodysplastic syndrome marrow originate from cells at a
pluripotent stem level and maintain their early differentiation
potency. Cancer Invest. 33:369–377. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith MA, Choudhary GS, Pellagatti A, Choi
K, Bolanos LC, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan
K, Steeples V, et al: U2AF1 mutations induce oncogenic IRAK4
isoforms and activate innate immune pathways in myeloid
malignancies. Nat Cell Biol. 21:640–650. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kennedy AL and Shimamura A: Genetic
predisposition to MDS: Clinical features and clonal evolution.
Blood. 133:1071–1085. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nolte F and Hofmann WK: Molecular
mechanisms involved in the progression of myelodysplastic syndrome.
Future Oncol. 6:445–455. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Issa JP: Epigenetic changes in the
myelodysplastic syndrome. Hematol Oncol Clin North Am. 24:317–330.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Z, Zhao L, Wei X, Guo Q, Zhu X, Wei
R, Yin X, Zhang Y, Wang B and Li X: Integrated bioinformatic
analysis of microarray data reveals shared gene signature between
MDS and AML. Oncol Lett. 16:5147–5159. 2018.PubMed/NCBI
|
|
9
|
Gao J, Chang YS, Jallal B and Viner J:
Targeting the insulin-like growth factor axis for the development
of novel therapeutics in oncology. Cancer Res. 72:3–12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guerreiro AS, Boller D, Doepfner KT and
Arcaro A: IGF-IR: Potential role in antitumor agents. Drug News
Perspect. 19:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Strömberg T, Ekman S, Girnita L, Dimberg
LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K,
Osterborg A, et al: IGF-1 receptor tyrosine kinase inhibition by
the cyclolignan PPP induces G2/M-phase accumulation and apoptosis
in multiple myeloma cells. Blood. 107:669–678. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tazzari PL, Tabellini G, Bortul R, Papa V,
Evangelisti C, Grafone T, Martinelli G, McCubrey JA and Martelli
AM: The insulin-like growth factor-I receptor kinase inhibitor
NVP-AEW541 induces apoptosis in acute myeloid leukemia cells
exhibiting autocrine insulin-like growth factor-I secretion.
Leukemia. 21:886–896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shi P, Chandra J, Sun X, Gergely M, Cortes
JE, Garcia-Manero G, Arlinghaus RB, Lai R and Amin HM: Inhibition
of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest
in imatinib-resistant chronic myeloid leukaemia cells. J Cell Mol
Med. 14:1777–1792. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Whelan JT, Ludwig DL and Bertrand FE:
HoxA9 induces insulin-like growth factor-1 receptor expression in
B-lineage acute lymphoblastic leukemia. Leukemia. 22:1161–1169.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schillaci R, Galeano A, Becu-Villalobos D,
Spinelli O, Sapia S and Bezares RF: Autocrine/paracrine involvement
of insulin-like growth factor-I and its receptor in chronic
lymphocytic leukaemia. Br J Haematol. 130:58–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Malaguarnera R and Belfiore A: The
emerging role of insulin and insulin-like growth factor signaling
in cancer stem cells. Front Endocrinol (Lausanne). 5:102014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Muraguchi T, Nanba D, Nishimura EK and
Tashiro T: IGF-1R deficiency in human keratinocytes disrupts
epidermal homeostasis and stem cell maintenance. J Dermatol Sci.
94:298–305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Teng CF, Jeng LB and Shyu WC: Role of
insulin-like growth factor 1 receptor signaling in stem cell
stemness and therapeutic efficacy. Cell Transplant. 27:1313–1319.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qi H, Xiao L, Lingyun W, Ying T, Yi-Zhi L,
Shao-Xu Y and Quan P: Expression of type 1 insulin-like growth
factor receptor in marrow nucleated cells in malignant
hematological disorders: Correlation with apoptosis. Ann Hematol.
85:95–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Q, Li X, Zhang Z, Zhang Q, Xu F, Yang
L, Tao Y and Liu Y: Overexpression of IGF-IR in malignant clonal
cells in bone marrow of myelodysplastic syndromes. Cancer Invest.
28:983–988. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He Q, Chang CK, Xu F, Zhang QX, Shi WH and
Li X: Purification of bone marrow clonal cells from patients with
myelodysplastic syndrome via IGF-IR. PLoS One. 10:e01403722015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valent P, Horny HP, Bennett JM, Fonatsch
C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger
O, et al: Definitions and standards in the diagnosis and treatment
of the myelodysplastic syndromes: Consensus statements and report
from a working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vardiman JW, Harris NL and Brunning RD:
The world health organization (WHO) classification of the myeloid
neoplasms. Blood. 100:2292–2302. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Delacrétaz F, Schmidt PM, Piguet D,
Bachmann F and Costa J: Histopathology of myelodysplastic
syndromes. The FAB classification (proposals) applied to bone
marrow biopsy. Am J Clin Pathol. 87:180–186. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greenberg P, Cox C, LeBeau MM, Morel P,
Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, et
al: International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shaffer LG and Tommerup N: ISCN: An
international system for human cytogenetics nomenclature. S Karger;
Basel 2005: 2005
|
|
27
|
Nakagawa T, Matozaki S, Murayama T,
Nishimura R, Tsutsumi M, Kawaguchi R, Yokoyama Y, Hikiji K, Isobe T
and Chihara K: Establishment of a leukaemic cell line from a
patient with acquisition of chromosomal abnormalities during
disease progression in myelodysplastic syndrome. Br J Haematol.
85:469–476. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hosono N: Genetic abnormalities and
pathophysiology of MDS. Int J Clin Oncol. 24:885–892. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu F, Wu LY, Chang CK, He Q, Zhang Z, Liu
L, Shi WH, Guo J, Zhu Y, Zhao YS, et al: Whole-exome and targeted
sequencing identify ROBO1 and ROBO2 mutations as
progression-related drivers in myelodysplastic syndromes. Nat
Commun. 6:88062015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gonçalves AC, Alves R, Baldeiras I,
Cortesão E, Carda JP, Branco CC, Oliveiros B, Loureiro L, Pereira
A, Nascimento Costa JM, et al: Genetic variants involved in
oxidative stress, base excision repair, DNA methylation, and folate
metabolism pathways influence myeloid neoplasias susceptibility and
prognosis. Mol Carcinog. 56:130–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yuen JS and Macaulay VM: Targeting the
type 1 insulin-like growth factor receptor as a treatment for
cancer. Expert Opin Ther Targets. 12:589–603. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Narla G, Sangodkar J and Ryder CB: The
impact of phosphatases on proliferative and survival signaling in
cancer. Cell Mol Life Sci. 75:2695–2718. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu Y, Li N, Xiang R and Sun P: Emerging
roles of the p38 MAPK and PI3K/AKT/mTOR pathways in
oncogene-induced senescence. Trends Biochem Sci. 39:268–276. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Q, Chen M, Liu H, Yang L, Yang T and He
G: The dual role of ERK signaling in the apoptosis of neurons.
Front Biosci (Landmark Ed). 19:1411–1417. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Paul M, Manikanta K, Hemshekhar M,
Sundaram MS, Naveen S, Ramesh TN, Kemparaju K and Girish KS:
Bisdemethoxycurcumin promotes apoptosis in human platelets via
activation of ERK signaling pathway. Toxicol In Vitro.
63:1047432019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang DX, Ma DY, Yao ZQ, Fu CY, Shi YX,
Wang QL and Tang QQ: ERK1/2/p53 and NF-κB dependent-PUMA activation
involves in doxorubicin-induced cardiomyocyte apoptosis. Eur Rev
Med Pharmacol Sci. 20:2435–2442. 2016.PubMed/NCBI
|
|
38
|
Navas TA, Mohindru M, Estes M, Ma JY,
Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, et
al: Inhibition of overactivated p38 MAPK can restore hematopoiesis
in myelodysplastic syndrome progenitors. Blood. 108:4170–4177.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bhagat TD, Zhou L, Sokol L, Kessel R,
Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski
T, et al: miR-21 mediates hematopoietic suppression in MDS by
activating TGF-β signaling. Blood. 121:2875–2881. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Follo MY, Mongiorgi S, Bosi C, Cappellini
A, Finelli C, Chiarini F, Papa V, Libra M, Martinelli G, Cocco L
and Martelli AM: The Akt/mammalian target of rapamycin signal
transduction pathway is activated in high-risk myelodysplastic
syndromes and influences cell survival and proliferation. Cancer
Res. 67:4287–4294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Boehrer S, Adès L, Braun T, Galluzzi L,
Grosjean J, Fabre C, Le Roux G, Gardin C, Martin A, de Botton S, et
al: Erlotinib exhibits antineoplastic off-target effects in AML and
MDS: A preclinical study. Blood. 111:2170–2180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ekman S, Frödin JE, Harmenberg J, Bergman
A, Hedlund A, Dahg P, Alvfors C, Ståhl B, Bergström S and Bergqvist
M: Clinical phase I study with an insulin-like growth factor-1
receptor inhibitor: Experiences in patients with squamous non-small
cell lung carcinoma. Acta Oncol. 50:441–447. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Sooman L, Wickström M, Fryknäs M,
Dyrager C, Lennartsson J and Gullbo J: Alternative cytotoxic
effects of the postulated IGF-IR inhibitor picropodophyllin in
vitro. Mol Cancer Ther. 12:1526–1536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rodrigues Alves APN, Fernandes JC,
Fenerich BA, Coelho-Silva JL, Scheucher PS, Simões BP, Rego EM,
Ridley AJ, Machado-Neto JA and Traina F: IGF1R/IRS1 targeting has
cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in
acute lymphoblastic leukemia cells. Cancer Lett. 456:59–68. 2019.
View Article : Google Scholar : PubMed/NCBI
|
